Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Walloon Brabant

Oct 17, 2013, 05:47 ET from Cardio3 BioSciences

MONT-SAINT-GUIBERT, Belgium, October 17, 2013 /PRNewswire/ --

The Belgian biotechnology company Cardio3 BioSciences (C3BS), leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, is pleased to announce that it has won the Trends-Tendances Business Tour 2013 Award in the "Innovation" category for the Walloon Brabant region.

The Trends-Tendances Business Tour is an initiative from the magazine and its Dutch counterpart Trends, in collaboration with Wallonia Foreign Trade & Investment Agency (AWEX) and Business & Society. The Business Tour showcases three companies in each province in the country in three different fields: sustainable management, export and innovation. The choice of these companies has been made ​​by the editors of the magazine and BDO, partner of the event. The chosen businesses are iconic companies in their field and have a profile that stands out in the economic landscape.

Cardio3 BioSciences' most advanced therapy, C-Cure®, involves taking cells from a patient's bone marrow and through a proprietary process called Cardiopoiesis re-programming those cells so that they become heart precursor cells. The cells, known as cardiopoietic cells, are then injected back into the patient's heart through a minimally invasive procedure using a proprietary catheter called
C-Cathez® with the goal of repairing damaged tissue and improving heart function, clinical outcomes and quality of life. C-Cure® is in a Phase III clinical trial in Europe. The trial, called CHART-1, represents the world's first Phase III trial for a pre-programmed cellular therapy targeting heart failure.

C-Cure® builds on research conducted at Mayo Clinic (Rochester, Minnesota, USA), Cardio3 BioSciences (Mont-Saint-Guibert, Belgium) and Cardiovascular Centre Aalst (Aalst, Belgium). The research has been published in  major international journals and has been recognised prestigious awards in the United States.

Dr Christian Homsy, CEO of Cardio3 BioSciences, said: "Winning Trends-Tendances' Business Tour Most Innovative Company Award in a province that is the home of so many innovative businesses is a great honor for our employees and investors, and reflects the truly world class research and development Cardio3 BioSciences has employed to bring C-Cure® from scientific breakthrough to first use in humans. We aim for C-Cure® to be the first approved regenerative product for ischaemic heart failure and look forward to continuing the contribute to the success of Belgian biotechnology."

About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure® is an innovative pharmaceutical product that is being developed for heart failure indication.  C-Cure® consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle cells that behave identically to those lost to heart disease. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath®ez, the most technologically injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.  

Cardio3 BioSciences' shares are listed on NYSE Euronext Brussels and NYSE Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities. As a result, of these factors investors and prospective investors are cautioned not to rely on any forward-looking statements.  We disclaim any intention or obligation to update or review any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information contact:

Cardio3 BioSciences
Dr Christian Homsy, CEO
Anne Portzenheim, Communication Manager
Tel : +32-10-39-41-00

Citigate Dewe Rogerson
Chris Gardner
Tel : +44(0)207-638-9571

SOURCE Cardio3 BioSciences